Iovance Biotherapeutics (IOVA) Gets a Buy Rating from Chardan Capital


In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Iovance Biotherapeutics (IOVA), with a price target of $50.00. The company’s shares closed last Thursday at $40.42, close to its 52-week high of $41.49.

According to TipRanks.com, Livshits is a 5-star analyst with an average return of 40.0% and a 67.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Crispr Therapeutics AG, and Logicbio Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Iovance Biotherapeutics with a $46.20 average price target, a 15.5% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $55.00 price target.

See today’s analyst top recommended stocks >>

Based on Iovance Biotherapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $63.02 million. In comparison, last year the company had a GAAP net loss of $47.55 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients’ tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts